Corporate ActionMay 8, 2026, 09:07 AM
BridgeBio Pharma Establishes $500M At-The-Market Equity Offering
AI Summary
BridgeBio Pharma, Inc. has entered into a new Equity Distribution Agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC to establish an "at-the-market" offering program. This program allows the company to issue and sell up to $500 million of its common stock from time to time. Concurrently, the company terminated its previous Equity Distribution Agreement dated May 4, 2023, with the same sales agents.
Key Highlights
- BridgeBio Pharma established an "at-the-market" equity offering program.
- The company may issue and sell up to $500,000,000 in common stock.
- Goldman Sachs & Co. LLC and Leerink Partners LLC will act as sales agents.
- Sales agents will receive a commission of up to 3.0% of gross proceeds.
- The previous Equity Distribution Agreement from May 4, 2023, was terminated.